Literature DB >> 20683153

Conflicting views on the molecular structure of the cancer antigen CA125/MUC16.

Houda Bouanene1, Abdelhédi Miled.   

Abstract

CA125 is a tumor antigen used to monitor the progression and regression of epithelial ovarian cancer. Despite the widespread use of CA125, the biochemical and molecular nature of this antigen is poorly understood. Analysis of the structure of CA125 is essential for determining the physiological role of this very significant tumor marker. Accumulated experimental evidence has shown that CA125 epitopes reside on a molecule of very complex architecture in terms of both protein backbone and oligosaccharide structures. It is not clear whether the heterogeneity of CA125 molecular characteristics are due to the variability of biological sources from which the molecule was isolated or to the different biophysical methods used for the characterization of all the oligosaccharides linked to CA125 or to the presence of glycoisoforms for this protein. This review attempts to summarize emerging data related to molecular characteristics of CA125 and to compare approaches undertaken to reach a better understanding of molecular features of this tumor marker.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683153      PMCID: PMC3833668          DOI: 10.3233/DMA-2010-0719

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  10 in total

1.  Challenges related to developing serum-based biomarkers for early ovarian cancer detection.

Authors:  Phuong L Mai; Nicolas Wentzensen; Mark H Greene
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

2.  Biochemical and morphological differences between CA125 isolated from healthy women and patients with epithelial ovarian cancer from Tunisian population.

Authors:  Houda Bouanène; Walid Saibi; Moncef Mokni; Badreddine Sriha; L Ben Fatma; H Ben Limem; S Ben Ahmed; Ali Gargouri; Abdelhédi Miled
Journal:  Pathol Oncol Res       Date:  2011-09-07       Impact factor: 3.201

Review 3.  Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers.

Authors:  Michela Chianca; Giorgia Panichella; Iacopo Fabiani; Alberto Giannoni; Serena L'Abbate; Alberto Aimo; Annamaria Del Franco; Giuseppe Vergaro; Chrysanthos Grigoratos; Vincenzo Castiglione; Carlo Maria Cipolla; Antonella Fedele; Claudio Passino; Michele Emdin; Daniela Maria Cardinale
Journal:  Front Cardiovasc Med       Date:  2022-07-06

4.  Cancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer.

Authors:  J Tang; Y Li; K Lyon; J Camps; S Dalton; T Ried; S Zhao
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

Review 5.  Deciphering the molecular nature of ovarian cancer biomarker CA125.

Authors:  Florian Weiland; Karina Martin; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-22       Impact factor: 6.208

6.  Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry.

Authors:  Florian Weiland; Katarina Fritz; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-09       Impact factor: 6.208

Review 7.  Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Authors:  Heather J Bax; Debra H Josephs; Giulia Pellizzari; James F Spicer; Ana Montes; Sophia N Karagiannis
Journal:  MAbs       Date:  2016-08-05       Impact factor: 5.857

Review 8.  CAR-T cell therapy in ovarian cancer: from the bench to the bedside.

Authors:  Xinxin Zhu; Han Cai; Ling Zhao; Li Ning; Jinghe Lang
Journal:  Oncotarget       Date:  2017-08-04

9.  Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.

Authors:  Ming-Xing Zhang; Shan-Shan Hong; Qing-Qing Cai; Meng Zhang; Jun Chen; Xiao-Yan Zhang; Cong-Jian Xu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

10.  CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels.

Authors:  Yi-Sheng Wang; Shi-Fang Ren; Wei Jiang; Jia-Qi Lu; Xiao-Yan Zhang; Xiao-Ping Li; Rui Cao; Cong-Jian Xu
Journal:  Ann Transl Med       Date:  2021-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.